01:37 , Jun 28, 2019 |  BC Innovations  |  Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
18:56 , Jun 17, 2019 |  BC Extra  |  Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
15:54 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting RXR could help treat melanoma. In a human melanoma cell line, the combination of a tool compound RXR inhibitor and Mekinist trametinib decreased colony formation and...
23:28 , Jul 13, 2018 |  BC Extra  |  Preclinical News

RXR a potential minimal residual disease target in melanoma

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance in melanoma. Cancer relapse is driven by...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and...
19:20 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

BerGenBio ASA (OSE:BGBIO) reported data from 19 patients with metastatic melanoma in a Phase Ib/II trial evaluating bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) or Tafinlar dabrafenib/Mekinist trametinib from...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
22:30 , Jan 4, 2018 |  BC Innovations  |  Strategy

Next generation resolutions

With a slew of landmark approvals in the last 18 months, FDA has solidified its commitment to advancing genetic diagnostics. Now the agency is turning to the outstanding challenges, with solutions on the horizon for...
23:12 , Jan 3, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Novartis' Tafinlar plus Mekinist for melanoma

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted and granted Priority Review to an sNDA for Tafinlar dabrafenib (GSK2118436) plus Mekinist trametinib as an adjuvant treatment for patients with stage III melanoma with BRAF V600E or...